Company Overview
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor Pro, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers cervical products comprising Spider cervical plating, Streamline OCT system, and CervAlign systems; thoracolumbar products, such as of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; Silex sacroiliac joint fusion systems; interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; Contact ALP (Anterior Lumbar Plate) System; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain. The company is headquartered in Belgrade, Montana.
Why Investors Should Care
Return on capital employed stands at 16.5%.
Net profit has compounded at 52.9% per year over the last five years.
Revenue has grown at a 32.2% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.32.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $133.93M (+14.2% YoY); net profit $4.97M.
- Trailing 12 Months Year-on-year growth — revenue -36.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 32.2%, profit CAGR 52.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 32.20% |
| 1 Year: | -36.50% |
Compounded Profit Growth
| 5 Years: | 52.87% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -23.21% |
| 6 Months: | -29.51% |
| 3 Months: | -17.31% |
| 1 Month: | +2.38% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)47.35 · Neutral
P/E of 42.98 is above the sector median of 27.41 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 32.2% over 5 years.
- Profit CAGR of 52.9% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 53.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | XTNT Xtant Medical Holdings, Inc. | 0.43 | 42.98 | $60.29M | 0.00% | 16.50% | 3.95% | 32.20% | 52.87% |
| 2 | LLY Eli Lilly and Company SPX | 1,148.84 | 40.85 | $1.02T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 256.35 | 29.74 | $617.09B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 250.94 | 122.41 | $443.36B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 130.20 | 36.68 | $321.57B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 169.64 | 26.30 | $263.09B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 574.30 | 31.54 | $213.42B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 385.16 | 26.78 | $207.87B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 32.90M | 35.41M | 33.26M | 32.36M | 20.88M |
| Cost of Revenue | - | 12.66M | 11.13M | 11.26M | 14.60M | 8.91M |
| Gross Profit | - | 20.24M | 24.28M | 21.99M | 17.75M | 11.97M |
| Operating Expenses | - | 19.18M | 19.66M | 19.45M | 18.70M | 14.89M |
| Operating Income | - | 1.06M | 4.62M | 2.54M | -944.00K | -2.92M |
| EBITDA | - | 2.15M | 5.98M | 3.63M | 4.13M | -1.93M |
| Interest Expense | - | 1.04M | 1.00M | 904.00K | 718.00K | 599.00K |
| Pretax Income | - | 33.00K | 3.81M | 1.56M | 1.60M | -3.06M |
| Tax Provision | - | -25.00K | 255.00K | 257.00K | 1.54M | 27.00K |
| Net Income | - | 58.00K | 3.55M | 1.31M | 57.00K | -3.09M |
| Diluted EPS | - | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 57.97M | 91.30M | 117.27M | 133.93M |
| Cost of Revenue | 25.83M | 35.84M | 49.05M | 49.65M |
| Gross Profit | 32.14M | 55.47M | 68.22M | 84.27M |
| Operating Expenses | 38.89M | 65.62M | 80.29M | 76.99M |
| Operating Income | -6.75M | -10.16M | -12.07M | 7.28M |
| EBITDA | -5.43M | 5.08M | -7.88M | 15.89M |
| Interest Expense | 1.69M | 2.94M | 4.16M | 3.67M |
| Pretax Income | -8.42M | -1.04M | -16.26M | 7.00M |
| Tax Provision | 69.00K | -1.70M | 187.00K | 2.03M |
| Net Income | -8.48M | 660.00K | -16.45M | 4.97M |
| Diluted EPS | -0.09 | 0.01 | -0.12 | 0.03 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 60.23M | 92.61M | 93.84M | 94.14M |
| Current Assets | - | 49.32M | 64.87M | 67.12M | 78.25M |
| Cash & Equivalents | - | 20.30M | 5.71M | 6.20M | 17.05M |
| Inventory | - | 17.29M | 36.88M | 38.63M | 30.26M |
| Receivables | - | 10.85M | 20.73M | 20.66M | 17.80M |
| Total Liabilities | - | 26.06M | 41.26M | 50.87M | 43.19M |
| Current Liabilities | - | 15.22M | 22.99M | 28.58M | 29.48M |
| Long Term Debt | - | 9.69M | 17.17M | 22.04M | 11.03M |
| Total Debt | - | 17.07M | 23.56M | 35.14M | 28.72M |
| Total Equity | - | 34.17M | 51.35M | 42.96M | 50.95M |
| Shares Outstanding | - | 108.87M | 130.18M | 139.05M | 140.04M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -5.34M | -9.52M | -11.90M | 12.55M |
| Investing Cash Flow | - | -1.56M | -24.78M | -3.73M | 7.90M |
| Financing Cash Flow | - | 9.02M | 19.69M | 16.07M | -9.57M |
| Capital Expenditure | - | -1.76M | -1.46M | -4.11M | -2.38M |
| Free Cash Flow | - | -7.11M | -10.97M | -16.01M | 10.16M |
| Net Change in Cash | - | 2.12M | -14.61M | 447.00K | 10.88M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 55.4% | 60.8% | 58.2% | 62.9% |
| Operating Margin % | -11.7% | -11.1% | -10.3% | 5.4% |
| Net Margin % | -14.6% | 0.7% | -14.0% | 3.7% |
| ROE % | -24.8% | 1.3% | -38.3% | 9.8% |
| ROCE % | -15.0% | -14.6% | -18.5% | 11.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Nantahala Capital Management, LLC | 48.76% | 68.39M | $29.40M |
| 2 | AWM Investment Company, Inc. | 4.26% | 5.98M | $2.57M |
| 3 | Vanguard Capital Management LLC | 1.44% | 2.01M | $865.88K |
| 4 | Renaissance Technologies, LLC | 0.70% | 987.41K | $424.39K |
| 5 | Geode Capital Management, LLC | 0.38% | 529.21K | $227.46K |
| 6 | Crescent Grove Advisors, Llc | 0.29% | 412.02K | $177.09K |
| 7 | Hillsdale Investment Management Inc. | 0.26% | 362.20K | $155.67K |
| 8 | Nano Cap New Millennium Growth Fund L P | 0.25% | 350.00K | $150.43K |
| 9 | Vanguard Fiduciary Trust Co | 0.18% | 257.99K | $110.88K |
| 10 | Acadian Asset Management. LLC | 0.13% | 180.30K | $77.49K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for XTNT
XTNT — Frequently Asked Questions
What is the current share price of Xtant Medical Holdings, Inc. (XTNT)?
As of 2026-08-02 19:16 PDT, Xtant Medical Holdings, Inc. (XTNT) trades at $0.43 on NYSE American. Its 52-week range is $0.39 to $0.92.
What is the market capitalisation of XTNT?
Xtant Medical Holdings, Inc. (XTNT) has a market capitalisation of $60.29M on NYSE American.
What is the P/E ratio of XTNT?
XTNT trades at a trailing price-to-earnings (P/E) ratio of 42.98. The industry average P/E is 27.41. Its price-to-book (P/B) ratio is 1.24.
What is the return on equity (ROE) of XTNT?
XTNT has a return on equity (ROE) of 3.95%. Its return on capital employed (ROCE) is 16.50%.
Is XTNT a good stock to buy?
This page provides a data-driven analysis of Xtant Medical Holdings, Inc. (XTNT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.